Overview

The Repatriation Medical Authority Instrument No. 45 of 2011, enacted under the Veterans’ Entitlements Act 1986, addresses specific medical conditions related to myelodysplastic disorder, particularly those associated with exposure to ionising radiation and treatments involving radioactive substances. This instrument was introduced to provide a comprehensive review and amendment of the existing Statement of Principles Instrument No. 37 of 2006, aiming to clarify and expand the criteria for eligibility for certain veterans’ benefits. The Authority's determination aims to ensure that the legislative framework accurately reflects the latest medical understanding and provides appropriate compensation for affected veterans. The enactment was overseen by the Repatriation Medical Authority, with the policy objective of ensuring fair and just treatment for veterans suffering from conditions linked to their service.

Scope and Application

The Repatriation Medical Authority Instrument No. 45 of 2011 amends the Statement of Principles Instrument No. 37 of 2006 concerning myelodysplastic disorder under the Veterans’ Entitlements Act 1986 and the Military Rehabilitation and Compensation Act 2004. This legislative amendment applies to veterans and service personnel who have been diagnosed with myelodysplastic disorder, focusing on factors such as exposure to ionising radiation, treatment with radioactive iodine, and treatment with radioactive phosphorous. It also revises the definition of "cumulative equivalent dose" and removes the definitions of "a course of therapeutic radiation" and "atomic radiation". This Instrument has a national jurisdictional reach within Australia and is effective as of the date specified in accordance with the Legislative Instruments Act 2003. The Authority sought public input during the investigation phase but did not receive any submissions for consideration. The Instrument concludes the investigation process that was previously advertised in the Government Notices Gazettes on 1 September 2010 and 3 November 2010.

Key Provisions

The Repatriation Medical Authority Instrument No. 45 of 2011, under the Veterans’ Entitlements Act 1986 (VEA) and the Military Rehabilitation and Compensation Act 2004, amends Statement of Principles Instrument No. 37 of 2006. It introduces changes to the factors associated with myelodysplastic disorder, replacing certain existing factors with new ones concerning ionising radiation, treatment with radioactive iodine, and treatment with radioactive phosphorus (sections 2 and 3). Additionally, it revises the definition of "cumulative equivalent dose" and removes definitions related to "a course of therapeutic radiation" and "atomic radiation" (section 3). This legislative instrument provides a clear timeline for the effect of the amendment in accordance with the Legislative Instruments Act 2003 (subsection 12(1)(a)) (section 3). The Repatriation Medical Authority (RMA) undertook a thorough investigation process before determining this Instrument. The Authority advertised its intention to investigate myelodysplastic disorder in the Government Notices Gazettes on 1 September 2010 and 3 November 2010, reaching out to a wide array of organisations and individuals, including the Repatriation Commission and entities representing veterans and their dependants (sections 4 and 5). The RMA invited submissions from relevant parties and experts, although no submissions were received for consideration during the investigation (section 4). The finalisation of this Instrument marks the conclusion of the investigation into myelodysplastic disorder as advertised in the aforementioned Government Notices Gazettes (section 5). This Instrument imposes several obligations and requirements on parties governed by the VEA and related Acts. The RMA must ensure that all amendments are properly advertised and communicated to relevant stakeholders, including veterans, service personnel, and their representatives (section 4). The Authority must also ensure that any changes to the Statement of Principles are thoroughly investigated and justified, including the solicitation of expert opinions and public submissions (sections 4 and 5). Furthermore, any person or organisation seeking a list of references related to the condition must make a written request to the RMA (section 6). There are no specific offences, penalties, or consequences mentioned in the explanatory notes for breach of the provisions in this Instrument. However, given that the Repatriation Medical Authority operates under the legislative framework of the VEA and other related Acts, any failure to comply with the obligations or requirements stipulated could potentially lead to administrative or judicial consequences. These might include reviews by relevant authorities, appeals to higher tribunals, or other corrective actions as deemed necessary to ensure adherence to the legislative intent. The exact penalties or consequences would depend on the specific context and the applicable provisions of the overarching Acts.